EP Patent

EP2714033A1 — Combination therapy of hsp90 inhibitory compounds with chk inhibitors

Assigned to Synta Phamaceuticals Corp · Expires 2014-04-09 · 12y expired

What this patent protects

A pharmaceutical composition comprising a CHK inhibitor, and an Hsp90 inhibitor according to the following formulae or tautomers, or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treat…

USPTO Abstract

A pharmaceutical composition comprising a CHK inhibitor, and an Hsp90 inhibitor according to the following formulae or tautomers, or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical compositions described herein.

Drugs covered by this patent

Patent Metadata

Patent number
EP2714033A1
Jurisdiction
EP
Classification
—
Expires
2014-04-09
Drug substance claim
No
Drug product claim
No
Assignee
Synta Phamaceuticals Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.